0 patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
This portfolio holds none of the 4 US patents in force on its record. from the record
Of the 4 now held by other companies, 2 were conveyed to Hoffmann la Roche Inc. in the filing they arrived in, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2019 to 2042.
US 11,760,807
GPC3-Targeting Drug Which Is Administered To Patient Responsive To GPC3-Targeting Drug Therapy
May 8, 2035
US 12,195,547
Dosing for Combination Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody and ANTI-CD79B Antibody Drug Conjugate
Apr 29, 2042
20242029203420392042
4 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends May 2035 · High confidence
The most cited patent in this portfolio, cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2035.
now held by F. Hoffmann-La Roche AG
Also notable
Ends Mar 2037 · High confidence
The largest patent family in this portfolio, 7 related applications, renewed at 2 of 3 maintenance windows. Protection runs to 2037.
conveyed to Hoffmann la Roche Inc. - now held by Oryzon Genomics, S.A.
Also notable
Ends Apr 2042 · High confidence
Granted 2025. Too new for citation comparison; protection runs to 2042.
conveyed to Hoffmann-La Roche Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first.
Also on record: 4 patents in force now held by others · 4 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.